Across TCGA pan-cancer cohorts, RN7SKP153 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RN7SKP153’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where RN7SKP153 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SKP153 is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.
PRAD and LIHC are the cancer types where RN7SKP153 tumor–normal differential expression is most reproducible.